Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 45 WIGGINS AVENUE BEDFORD MA 01730 |
Tel: | N/A |
Website: | https://www.stoketherapeutics.com |
IR: | See website |
Key People | ||
Edward M. Kaye Chief Executive Officer, Director | Thomas Leggett Chief Financial Officer | Huw M. Nash Chief Operating Officer, Chief Business Officer |
Jonathan Allan General Counsel, Company Secretary | Jason Hoitt Chief Commercial Officer | Barry S. Ticho Chief Medical Officer |
Business Overview |
Stoke Therapeutics, Inc. is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with ribonucleic acid (RNA)-based medicines. The Company, through its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach, is engaged in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. TANGO aims to restore missing proteins by increasing or stoking protein output from healthy genes, thus compensating for the non-functioning copy of the gene. The Company is pursuing the development of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. The Company's initial focus is haploinsufficiency and diseases of the central nervous system and the eye. |
Financial Overview |
For the three months ended 31 March 2024, Stoke Therapeutics Inc revenues decreased 18% to $4.2M. Net loss increased 17% to $26.4M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development - Balancing val increase of 17% to $20.3M (expense), Other expense, net decrease from $42K (income) to $428K (expense). |